GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study
- PMID: 2565752
- DOI: 10.1016/0006-8993(89)90373-9
GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study
Abstract
The administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice results in the loss of dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) from the mouse striatum and a loss of cells containing tyrosine hydroxylase (TH)-immunoreactivity from the substantia nigra. The cells that remained in the nigra after MPTP treatment were smaller in diameter than normal cells. Treatment with GM1 ganglioside beginning 24 h after establishing the MPTP lesion resulted in partial restoration of DA and DOPAC content in the striatum and an increase in the diameter of the TH-immunoreactive nigra cells. It appears, therefore, that treatment of MPTP-intoxicated mice with GM1 ganglioside results in the partial restoration of both the biochemistry and morphology of dopaminergic neurons.
Similar articles
-
GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism.Exp Neurol. 1989 Aug;105(2):177-83. doi: 10.1016/0014-4886(89)90117-9. Exp Neurol. 1989. PMID: 2568945
-
[Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].No To Shinkei. 1990 Nov;42(11):1035-40. No To Shinkei. 1990. PMID: 2076347 Japanese.
-
Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.Science. 1992 May 8;256(5058):843-6. doi: 10.1126/science.1350379. Science. 1992. PMID: 1350379
-
Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.Mol Chem Neuropathol. 1989 Jun;10(3):171-83. doi: 10.1007/BF03159727. Mol Chem Neuropathol. 1989. PMID: 2669769 Review. No abstract available.
-
Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review.Acta Neurol Scand Suppl. 1991;136:29-36. doi: 10.1111/j.1600-0404.1991.tb05017.x. Acta Neurol Scand Suppl. 1991. PMID: 1801534 Review.
Cited by
-
Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson's disease.Acta Pharmacol Sin. 2021 Apr;42(4):518-528. doi: 10.1038/s41401-020-0454-y. Epub 2020 Jul 28. Acta Pharmacol Sin. 2021. PMID: 32724177 Free PMC article.
-
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson's Disease.Front Neurosci. 2019 Apr 11;13:328. doi: 10.3389/fnins.2019.00328. eCollection 2019. Front Neurosci. 2019. PMID: 31031582 Free PMC article. Review.
-
Myelin Lipid Alterations in Neurodegenerative Diseases: Landscape and Pathogenic Implications.Antioxid Redox Signal. 2024 Dec;41(16-18):1073-1099. doi: 10.1089/ars.2024.0676. Epub 2024 Nov 22. Antioxid Redox Signal. 2024. PMID: 39575748 Review.
-
Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies.Am J Pathol. 2009 May;174(5):1891-909. doi: 10.2353/ajpath.2009.080680. Epub 2009 Apr 6. Am J Pathol. 2009. PMID: 19349362 Free PMC article.
-
Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.PLoS One. 2018 Jun 14;13(6):e0199189. doi: 10.1371/journal.pone.0199189. eCollection 2018. PLoS One. 2018. PMID: 29902255 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources